MAPT and Alzheimer disease: This would allow for more detailed investigations into whether BDNF Val66Met’s effects on CSF tau biomarkers differ across populations and whether the pattern of memory decline shown in Met66 carriers can be characterized by impairments in specific components of memory across the disease course of AD (e.g., delayed recall, recognition).